AarogyaAI aims to diagnose drug-resistant TB (DR-TB) using artificial intelligence in a few hours. We enable quick and accurate diagnosis of DR-TB so that the patient can be rightly prescribed effective drug combinations for treatment, instantly.
The co-founders, Praapti and Avlokita, are motivated by their life experiences to develop a solution for the growing challenges of DR-TB. Praapti, grew up in a family of doctors and was motivated to address public health issues using her scientific training in infectious diseases. Avlokita, lost her grandmother to tuberculosis and wanted to be a part of the solution working towards eliminating this disease.
In India today, Tuberculosis affects 2.7 million people each year, and thousands of people die because of it. However, there is a disproportionate focus on solving micro problems in research which, do not translate into public application. Our aim is to bridge that gap.
We are greatly inspired by Dr. Soumya Swaminathan, Chief Scientist at WHO and a tuberculosis physician. Dr.Swaminathan took a keen interest in our objectives and, is our mentor on this journey.
Tuberculosis claims more lives every year than AIDS. This is because, of the 19 anti-TB drugs available, doctors don’t always know which ones will work for whom. Thus, even though tuberculosis is curable, a delayed diagnosis of drug-resistant tuberculosis can mean patients are on ineffective medication for up to 7 years.
Currently, there are no tools to diagnose drug-resistant tuberculosis quickly and comprehensively. AarogyaAI aims to diagnose drug-resistant tuberculosis in a few hours so that a patient can be prescribed effective treatment, instantly. We use a DNA sequence from the patient which is uploaded to our SaaS. Our machine learning algorithm then gives an output report of a comprehensive drug susceptibility status of the patient.
In the long run, we will be able to predict the patterns of evolution of the bacteria and future drug resistance patterns. Our data analytics dashboard will provide valuable insight into bacterial phylogeny, its geographical influences amongst other statistics. This would greatly benefit public health programs in strategically placing PHCs as well as pharma companies to improve supply chain logistics and drug development.
We’ve been in the news a few times and are excited to share it with you.
Pitching for Aarogya AI was Praapti Jayaswal, who did her PhD in tuberculosis research and her co-founder, Avlokita Tiwari, a computational biologist, with an MA in bioinformatics.
AarogyaAI is backed by the UK-based Entrepreneur First. They have partnered with leading hospitals and diagnostic labs in the country.
Deep-tech investor Entrepreneur First (EF) completed its fifth Investor Day in Singapore that saw participation from 24 deep-tech companies from around Asia. It is EF’s largest cohort of startups so far.
PhD-holder Praapti Jayasawal and Computational Biologist Avlokita Tiwari have built an Artificial Intelligence (AI) enabled SaaS (Software as a Service) that diagnoses drug-resistant tuberculosis (DR-TB) and enable effective treatment, instantly. This is unlike the existing drug-resistant tuberculosis diagnostics, which takes four to six weeks